Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
DGRO vs IBB: how they differ
DGRO and IBB hold 2% of their weight in the same names, and IBB returned more over the year.
iShares Core Dividend Growth ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, DGRO and IBB hold 2% of their money in the same securities at the same weight.
| Holding | DGRO | IBB |
|---|---|---|
| AMGEN INC | 1.30% | 7.85% |
| GILEAD SCIENCES | 1.00% | 7.44% |
| BLK CSH FND TREASURY SL AGENCY | 0.06% | 0.12% |
| USD CASH | 0.18% | 0.05% |
| Only in DGRO | Only in IBB |
|---|---|
| MICROSOFT 3.45% | VERTEX PHARMACEUTICALS 7.94% |
| JOHNSON & JOHNSON 3.20% | REGENERON PHARMACEUTICALS 5.92% |
| JPMORGAN CHASE & CO 3.20% | ARGENX SE ADR 3.78% |
| EXXONMOBIL HOLDINGS CORP 3.07% | MODERNA 3.67% |
| APPLE 3.04% | NATERA 3.30% |
| ABBVIE 3.02% | REVOLUTION MEDICINES 2.87% |
| BROADCOM INC 2.38% | ALNYLAM PHARMACEUTICALS 2.44% |
| PROCTER & GAMBLE 2.16% | BIOGEN 2.33% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| DGRO iShares Core Dividend Growth ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | Core Dividend Growth | Biotechnology |
| Total return, 1 year | +17.4% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −0.1 pts | +24.0 pts |
| Expense ratio | 0.08% | 0.44% |
| Already in the S&P 500 | 94.7% | 35.6% |
| Holdings | 387 | 233 |
DGRO in plain words
DGRO is an index equity fund tracking the Core Dividend Growth. Over the year to Sep 11, 2026 it returned +17.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.08% a year. By its holdings filed for Sep 10, 2026, 95% of the fund by weight is stocks the S&P 500 also holds, across 387 positions, with the top ten at 27.8%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Sep 10, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 233 positions, with the top ten at 47.5%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, DGRO or IBB?
- In the year to Sep 13, 2026, with distributions reinvested, DGRO returned +17.4% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, DGRO or IBB?
- DGRO charges 0.08% a year and IBB charges 0.44%, so DGRO is cheaper. Fees come from each fund's prospectus.
- How much do DGRO and IBB overlap with the S&P 500?
- By their latest filed holdings, 95% of DGRO and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, DGRO against IBB, data as of Sep 13, 2026. https://etfiq.com/compare/any/dgro-vs-ibb Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources